Didanosine overdosage: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
== | ==Overdosage== | ||
There is no known antidote for VIDEX (didanosine) overdosage. In phase 1 studies, in which VIDEX was initially administered at doses ten times the currently recommended dose, toxicities included: pancreatitis, peripheral neuropathy, diarrhea, hyperuricemia, and hepatic dysfunction. Didanosine is not dialyzable by peritoneal dialysis, although there is some clearance by hemodialysis<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VIDEX (DIDANOSINE) POWDER, FOR SOLUTION [BRISTOL-MYERS SQUIBB COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4401ca0-98ae-af38-84c7-2f615d0706b9#nlm34089-3| publisher = | date = | accessdate = 1 January 2014 }}</ref>. | There is no known antidote for VIDEX (didanosine) overdosage. In phase 1 studies, in which VIDEX was initially administered at doses ten times the currently recommended dose, toxicities included: pancreatitis, peripheral neuropathy, diarrhea, hyperuricemia, and hepatic dysfunction. Didanosine is not dialyzable by peritoneal dialysis, although there is some clearance by hemodialysis<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VIDEX (DIDANOSINE) POWDER, FOR SOLUTION [BRISTOL-MYERS SQUIBB COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4401ca0-98ae-af38-84c7-2f615d0706b9#nlm34089-3| publisher = | date = | accessdate = 1 January 2014 }}</ref>. | ||
==References== | ==References== | ||
Revision as of 20:29, 1 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overdosage
There is no known antidote for VIDEX (didanosine) overdosage. In phase 1 studies, in which VIDEX was initially administered at doses ten times the currently recommended dose, toxicities included: pancreatitis, peripheral neuropathy, diarrhea, hyperuricemia, and hepatic dysfunction. Didanosine is not dialyzable by peritoneal dialysis, although there is some clearance by hemodialysis[1].
References
- ↑ "VIDEX (DIDANOSINE) POWDER, FOR SOLUTION [BRISTOL-MYERS SQUIBB COMPANY]". Retrieved 1 January 2014.
Adapted from the FDA Package Insert.